背景:急性髓性白血病(AML)是恶性恶性血液病。它对早期诊断提出了挑战,需要鉴定有效的生物标志物。本研究旨在通过荟萃分析评估长链非编码RNA(lncRNA)在AML诊断中的诊断准确性。该研究在PROSPERO网站上注册,编号为493518。
方法:在PubMed中进行了文献检索,Embase,Hinari,和Scopus数据库来确定相关研究。我们汇集了敏感性,特异性,正似然比(PLR),负似然比(NLR),诊断优势比(DOR),以及使用Stata14.1软件汇总接收器工作特性(ROC)下的区域。通过I2统计量和Cochran-Q检验确定研究之间的异质性。由于纳入研究的异质性显著,选择随机效应模型。进行Meta回归和亚组分析以评估异质性的潜在来源。此外,使用Deek漏斗图不对称检验估计潜在的发表偏倚。
结果:本次荟萃分析共纳入了14篇涵盖19项研究的文章,包括1588名AML患者和529名健康参与者。总体合并敏感性,特异性,PLR,NLR,DOR,汇总ROC曲线下面积为0.85(95%CI=0.78-0.91),0.82(95%CI=0.72-0.89),4.7(95%CI=2.9-7.4),0.18(95%CI=0.12-0.28),26(95%CI=12-53),和0.90(95%CI=0.87-0.93),分别。此外,来自非骨髓单个核细胞(BMMC)的lncRNAs具有优越的诊断价值,具有合并的敏感性,特异性,AUC分别为0.93、0.82和0.95。
结论:这项荟萃分析证明循环lncRNAs可以作为AML的潜在诊断标记。在非BMMClncRNAs中观察到诊断的高准确性,给定截止值,和使用的GADPH内参基因。然而,需要进一步的大样本量研究来证实我们的结果.
BACKGROUND: Acute myeloid
leukemia (AML) is aggressive type of hematological malignancy. Its poses challenges in early diagnosis, necessitating the identification of an effective biomarker. This study aims to assess the diagnostic accuracy of long noncoding RNAs (lncRNA) in the diagnosis of AML through a meta-analysis. The study is registered on the PROSPERO website with the number 493518.
METHODS: A literature search was conducted in the PubMed, Embase, Hinari, and the Scopus databases to identify relevant studies. We pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristics (ROC) using Stata 14.1 software. Heterogeneity between studies was determined through the I2 statistic and Cochran-Q test. A random effect model was chosen due to significant heterogeneity among included studies. Meta-regression and subgroup analysis were performed to assess the potential source of heterogeneity. Furthermore, potential publication bias was estimated using Deek\'s funnel plot asymmetry test.
RESULTS: A total of 14 articles covering 19 studies were included in this meta-analysis comprising 1588 AML patients and 529 healthy participants. The overall pooled sensitivity, specificity, PLR, NLR, DOR, and the area under the summary ROC curve were 0.85 (95% CI = 0.78-0.91), 0.82 (95% CI = 0.72-0.89), 4.7 (95% CI = 2.9-7.4), 0.18 (95% CI = 0.12-0.28), 26 (95% CI = 12-53), and 0.90 (95% CI = 0.87-0.93), respectively. Moreover, lncRNAs from non-bone marrow mononuclear cells (BMMC) had superior diagnostic value with pooled sensitivity, specificity, and AUC were 0.93, 0.82, and 0.95, respectively.
CONCLUSIONS: This meta-analysis demonstrated that circulating lncRNAs can serve as potential diagnostic markers for AML. High accuracy of diagnosis was observed in non-BMMC lncRNAs, given cutoff value, and the GADPH internal reference gene used. However, further studies with large sample size are required to confirm our results.